Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 120.77M | 151.93M | 188.67M | 199.73M | 128.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.77M | 151.93M | 188.67M | 199.73M | 128.94M |
| Cost of Revenue | 43.89M | 65.15M | 113.65M | 117.73M | 122.30M |
| Gross Profit | 76.89M | 86.78M | 75.01M | 82.01M | 6.64M |
| SG&A Expenses | 23.29M | 29.36M | 35.81M | 38.78M | 38.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.40M | 114.35M | 169.29M | 202.95M | 207.27M |
| Operating Income | 44.37M | 37.59M | 19.38M | -3.22M | -78.33M |
| Income Before Tax | 32.72M | 23.41M | 5.76M | -15.68M | -85.42M |
| Income Tax Expenses | 31.00K | 12.00K | -33.00K | -36.00K | -12.00K |
| Earnings from Continuing Operations | 32.69 | 23.40 | 5.80 | -15.64 | -85.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.69M | 23.40M | 5.80M | -15.64M | -85.40M |
| EBIT | 44.37M | 37.59M | 19.38M | -3.22M | -78.33M |
| EBITDA | 48.47M | 41.73M | 24.88M | 2.24M | -73.28M |
| EPS Basic | 3.16 | 2.22 | -0.39 | -3.69 | -12.87 |
| Normalized Basic EPS | 2.49 | 2.04 | 0.40 | -1.70 | -7.48 |
| EPS Diluted | 3.12 | 2.18 | -0.43 | -3.72 | -12.87 |
| Normalized Diluted EPS | 2.47 | 2.02 | 0.38 | -1.72 | -7.48 |
| Average Basic Shares Outstanding | 50.15M | 47.24M | 41.14M | 35.08M | 29.94M |
| Average Diluted Shares Outstanding | 50.35M | 47.44M | 41.34M | 35.17M | 29.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |